Claims for Patent: 4,705,685
✉ Email this page to a colleague
Summary for Patent: 4,705,685
| Title: | Methods and materials for treatment of disease states involving immunological factors |
| Abstract: | In animals including humans, the symptoms of non-anaphylactic disease states wherein the disease victim\'s humoral and/or cell-mediated immunological response is involved in disease pathology are alleviated upon administration of compositions comprising mixtures of histamine and one or more immunogenic substances participative in the humoral or cell-mediated pathogenic response. In preferred embodiments, the compositions are administered in essentially minute, \"neutralizing\" doses. Illustratively, significant relief of symptoms of multiple sclerosis is achieved through parenteral (e.g., subcutaneous or sublingual) administration of mixtures of histamine and measles virus immunogen. For a majority of patients, from about 8.8.times.10.sup.-6 to 5.5.times.10.sup.-3 mg of histamine phosphate will provide an effective quantity of histamine to a unit dose of the mixture. Likewise, a unit does of the mixture will contain from about 2.times.10.sup.-3 to about 4.times.10.sup.-4 times the prescribed vaccination dose of a killed, attenuated measles virus vaccine strain. As another example, rheumatoid arthritis symptoms are alleviated by administration of histamine admixed with an immunoglobulin G immunogen which is provocative of in vivo rheumatoid factor production. Other immune disorders (e.g., chronic pain and herpes simplex type II infections) are effectively treated with admixtures of histamine and appropriate immunogen(s). |
| Inventor(s): | McMichael; John (Cambridge Springs, PA) |
| Assignee: | |
| Application Number: | 06/708,274 |
| Patent Claims: | 1. A method for alleviating chronic pain symptoms comprising administering to the disease victim an effective amount of a composition comprising a mixture of histamine and
inactivated, attenuated measles virus or an immunologically active fraction thereof.
2. The method of claim 1 wherein histamine is admistered in the form of a water soluble histamine salt. 3. The method of claim 1 wherein said composition comprises in unit dosage form, from about 8.8.times.10.sup.-6 to about 5.5.times.10.sup.-3 mg of histamine phosphate. 4. The method of claim 1 wherein the measles virus is an inactivated, attenuated vaccine strain. 5. The method of claim 1 wherein said composition comprises, in unit dosage form, from about 2.times.10.sup.-3 to about 4.times.10.sup.-4 times the prescribed vaccination dose of an inactivated, attenuated measles virus vaccine strain. 6. The method of claim 1 wherein said composition is administered parenterally. 7. The method of claim 6 wherein said composition is administered subcutaneously or sublingually. |
Details for Patent 4,705,685
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Alk-abello, Inc. | HISTATROL | positive skin test control-histamine | Injection | 103754 | September 29, 1950 | ⤷ Start Trial | 2005-03-05 |
| Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | March 13, 1924 | ⤷ Start Trial | 2005-03-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
